Alphamab Oncology (FRA:3NK)
Germany
· Delayed Price · Currency is EUR 1.150
+0.050 (4.55%)
At close: Dec 4, 2025
Alphamab Oncology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 785.96 | 640.08 | 218.77 | 166.85 | 146.02 | - | Upgrade
|
| Revenue | 785.96 | 640.08 | 218.77 | 166.85 | 146.02 | - | Upgrade
|
| Revenue Growth (YoY) | 207.17% | 192.58% | 31.12% | 14.26% | - | - | Upgrade
|
| Cost of Revenue | 60.77 | 60.32 | 55.24 | 44.21 | 3.03 | - | Upgrade
|
| Gross Profit | 725.19 | 579.77 | 163.54 | 122.64 | 142.99 | - | Upgrade
|
| Selling, General & Admin | 74.99 | 75.11 | 79.56 | 86.94 | 77.55 | 78.21 | Upgrade
|
| Research & Development | 462.15 | 403.65 | 407.3 | 468.07 | 481.06 | 331.24 | Upgrade
|
| Operating Expenses | 537.13 | 478.76 | 486.86 | 555.01 | 558.61 | 409.45 | Upgrade
|
| Operating Income | 188.06 | 101.01 | -323.33 | -432.37 | -415.62 | -409.45 | Upgrade
|
| Interest Expense | -8.31 | -9.92 | -12.18 | -14.21 | -13.18 | -11.83 | Upgrade
|
| Interest & Investment Income | 38.7 | 49.26 | 74.04 | 33.87 | 27.81 | 64.66 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.5 | 13.45 | 33.19 | 66.71 | -41.41 | -122.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.85 | 12.56 | 17.68 | 20.28 | 29.99 | 51 | Upgrade
|
| EBT Excluding Unusual Items | 232.81 | 166.34 | -210.59 | -325.72 | -412.42 | -427.77 | Upgrade
|
| Pretax Income | 232.81 | 166.34 | -210.59 | -325.72 | -412.42 | -427.77 | Upgrade
|
| Earnings From Continuing Operations | 232.81 | 166.34 | -210.59 | -325.72 | -412.42 | -427.77 | Upgrade
|
| Net Income | 232.81 | 166.34 | -210.59 | -325.72 | -412.42 | -427.77 | Upgrade
|
| Net Income to Common | 232.81 | 166.34 | -210.59 | -325.72 | -412.42 | -427.77 | Upgrade
|
| Shares Outstanding (Basic) | 961 | 962 | 960 | 937 | 935 | 930 | Upgrade
|
| Shares Outstanding (Diluted) | 995 | 984 | 960 | 937 | 935 | 930 | Upgrade
|
| Shares Change (YoY) | 3.37% | 2.53% | 2.50% | 0.11% | 0.62% | 73.29% | Upgrade
|
| EPS (Basic) | 0.24 | 0.17 | -0.22 | -0.35 | -0.44 | -0.46 | Upgrade
|
| EPS (Diluted) | 0.24 | 0.17 | -0.22 | -0.35 | -0.44 | -0.46 | Upgrade
|
| Free Cash Flow | 217.62 | 190.56 | -239.02 | -429.96 | -478.72 | -438 | Upgrade
|
| Free Cash Flow Per Share | 0.22 | 0.19 | -0.25 | -0.46 | -0.51 | -0.47 | Upgrade
|
| Gross Margin | 92.27% | 90.58% | 74.75% | 73.50% | 97.93% | - | Upgrade
|
| Operating Margin | 23.93% | 15.78% | -147.79% | -259.14% | -284.63% | - | Upgrade
|
| Profit Margin | 29.62% | 25.99% | -96.26% | -195.22% | -282.44% | - | Upgrade
|
| Free Cash Flow Margin | 27.69% | 29.77% | -109.26% | -257.70% | -327.84% | - | Upgrade
|
| EBITDA | 251.82 | 165.36 | -267.54 | -391.83 | -387.1 | -390.47 | Upgrade
|
| EBITDA Margin | 32.04% | 25.83% | -122.29% | -234.85% | -265.10% | - | Upgrade
|
| D&A For EBITDA | 63.76 | 64.35 | 55.78 | 40.54 | 28.52 | 18.98 | Upgrade
|
| EBIT | 188.06 | 101.01 | -323.33 | -432.37 | -415.62 | -409.45 | Upgrade
|
| EBIT Margin | 23.93% | 15.78% | -147.79% | -259.14% | -284.63% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.